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Abstract
Background:  Bacterial adhesion is an important determinant of colonization and infection,
including dental caries. The salivary scavenger receptor cysteine-rich glycoprotein gp-340, which
mediates adhesion of Streptococcus mutans (implicated in caries), harbours three major size variants,
designated gp-340 I to III, each specific to an individual saliva. Here we have examined the
association of the gp-340 I to III polymorphisms with caries experience and adhesion of S. mutans.
Methods: A case-referent study was performed in 12-year-old Swedish children with high (n = 19)
or low (n = 19) caries experiences. We measured the gp-340 I to III saliva phenotypes and
correlated those with multiple outcome measures for caries experience and saliva adhesion of S.
mutans using the partial least squares (PLS) multivariate projection technique. In addition, we used
traditional statistics and 2-year caries increment to verify the established PLS associations, and
bacterial adhesion to purified gp-340 I to III proteins to support possible mechanisms.
Results: All except one subject were typed as gp-340 I to III (10, 23 and 4, respectively). The gp-
340 I phenotype correlated positively with caries experience (VIP = 1.37) and saliva adhesion of S.
mutans Ingbritt (VIP = 1.47). The gp-340 II and III phenotypes tended to behave in the opposite way.
Moreover, the gp-340 I phenotype tended to show an increased 2-year caries increment compared
to phenotypes II/III. Purified gp-340 I protein mediated markedly higher adhesion of S. mutans
strains Ingbritt and NG8 and Lactococcus lactis expressing AgI/II adhesins (SpaP or PAc) compared
to gp-340 II and III proteins. In addition, the gp-340 I protein appeared over represented in subjects
positive for Db, an allelic acidic PRP variant associated with caries, and subjects positive for both
gp-340 I and Db tended to experience more caries than those negative for both proteins.
Conclusion: Gp-340 I behaves as a caries susceptibility protein.
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Background
Dental caries is one of the most prevalent human infec-
tious diseases with life style and genetic factors modifying
disease activity [1-4]. The skewed distribution of caries in
Western populations today and its weak association with
traditional life style factors, e.g. sugar intake and oral
hygiene [5], suggest genetic components in caries devel-
opment. Early arguments for a genetic predisposal came
from twin studies [6] and the Vipeholm study [1] showing
large individual differences in caries development in spite
of similar exposures to sugars.
Dental caries is a mixed species infection caused by an
ecological shift from commensal toward cariogenic strep-
tococci [2-4], including Streptococcus mutans [3]. Among
potential caries susceptibility alleles or proteins are
accordingly multiple salivary proteins [7], e.g. salivary
agglutinin/gp-340 [8-10] and proline-rich proteins
(PRPs) [10-12], involved in oral biofilm formation, tissue
homeostasis and immunological surveillance [13-15].
While salivary agglutinin mediates aggregation (clear-
ance) and adhesion (colonization) of S. mutans and other
streptococci [16-18], PRPs primarily attach commensal
streptococci and actinomycetes to teeth [13]. Accordingly,
caries resistant subjects coincided with increased adhesion
of commensal Actinomyces and the highly prevalent allelic
PRP variants PRP-1 and PRP-2 [10]. By contrast, caries
prone subjects coincided with increased saliva adhesion
of S. mutans and Db, a low prevalence allelic acidic PRP
variant [10]. Salivary agglutinin is the major adhesion and
aggregation factor in saliva for S. mutans and is targeted by
its major surface adhesin polypeptide, antigen I/II (AgI/II)
[19]. Oral viridans streptococci generally express con-
served, but species-specific, AgI/II polypeptides [19].
However, while the AgI/II adhesin SpaP (or PAc)
expressed by S. mutans is the principal surface adhesin
interacting with gp-340, the commensal organism Strepto-
coccus gordonii expresses additional gp-340-interacting
adhesins, including Hsa [20,21]. The AgI/II polypeptides
interact with host cells and are potent activators of cell-
mediated responses [19,22], and have been used for vac-
cine and anti-adhesion protection against S. mutans and
dental caries [23,24]. We have shown salivary agglutinin
to be identical to the scavenger receptor cysteine-rich glyc-
oprotein gp-340 [9] and found three prevalent size vari-
ants of saliva gp-340, designated gp-340 I to III, each
specific to individual donors [25]. However, the gp-340 I
to III size polymorphisms have not been investigated as
relates to susceptibility or resistance to dental caries or to
differences in AgI/II-mediated adhesion of S. mutans.
Gp-340 [8,9,26] or DMBT1 (deleted in malignant brain
tumour, [27]) are protein homologs, encoded by the same
dmbt1 gene. They are mucin-like multidomain proteins,
composed of 14 repeating scavenger receptor cysteine-rich
SRCR domains intercalated by SID domains and followed
by CUB and ZP domains. In saliva, gp-340 exists as an oli-
gomer complexed with secretory immunoglobulin A (S-
IgA) [16,28]. Salivary gp-340/agglutinin aggregates a wide
array of bacteria and viruses via O-glycosylated Ser/Thr-
rich SID repeats and N-glycans [9,20,29,30]. It behaves
differently in fluid versus surface adsorbed form [20,21].
While fluid phase gp-340 aggregates only certain strepto-
coccal phenotypes, surface adsorbed gp-340 selectively
adhere other phenotypes (even of the same bacterial spe-
cies) [20,21]. Moreover, the SRCR, CUB and ZP domains
interact with multiple protein ligands [14]: SpD and SpA
collectins [31], lactoferrin [32], complement factor C1q
[33], S-IgA [28], and with MUC5B [34]. Gp-340/DMBT1
are present on macrophages, in lung and brain tissues and
in gastric and intestinal mucosa [26], and activate macro-
phages [31] and PMN cells as well as affect the differenti-
ation mode of epithelial cells [14]. Accordingly, the gp-
340/DMBT1 proteins are considered pattern recognition
molecules in various host innate defences [14].
The partial least squares (PLS) multivariate projection
technique derives its usefulness from its ability to deal
with multiple and noisy variables and multicollinearity in
data structures [35,36]. The PLS technique is designed to
handle multiple variables measured on relatively few sub-
jects (so-called “short and fat” data structures) compared
to traditional statistics that measures a few variables on
many subjects (so-called “long and lean” data structures).
It has been applied in genomics, proteomics and metabo-
nomics [36], in biochemistry to delineate the chemical
features of the RGRPQ peptide derived from the caries
resistance PRP-1 polypeptide [37,38], and to delineate
biomarkers or other clinical traits in human diseases
[36,10,39].
The aim of the present study was to utilize the PLS method
to correlate the gp-340 I to III size variants with caries
experience and saliva adhesion of S. mutans in children
with high (n = 19) or low (n = 19) caries experience, as
well as to substantiate possible mechanisms behind iden-
tified associations. The results reveal a positive association
of gp-340 I with both caries experience and saliva adhe-
sion of S. mutans, and that purified gp-340 I protein medi-
ates increased AgI/II-mediated adhesion of S. mutans.
Methods
Study groups, clinical recordings and saliva measurements
Twelve-year-old high caries cases (n = 19) and low caries
referents (n = 19) from three Public Dental Health Clinics
in Sweden were used in the present study. The 12-year-old
children were nested within the northern portion of a
Swedish nationwide cohort study of 3,400 children
[5,10]. The cases were randomly selected from the chil-
dren with 4 or more new enamel/dentin lesions duringBMC Infectious Diseases 2007, 7:57 http://www.biomedcentral.com/1471-2334/7/57
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the latest year (mean baseline DMFS = 5.0), and the refer-
ents were matched for gender and living area from caries
free individuals (baseline DMFS = 0). Caries was recorded
at base-line and after 2 years (2-year increment of dentin
and enamel lesions). The study was approved by the Eth-
ics Committee at Umeå University, Umeå, Sweden.
Data collection and saliva analyses were largely performed
as described [5,10]. Briefly, a questionnaire was used for
analyses of life style factors, e.g. sugar intake, oral hygiene,
fluoride exposure etc, and fresh whole saliva for analyses
of saliva factors, e.g. flow rate, pH, buffer capacity etc.
Parotid saliva, collected on ice using Lashley cups and 3 %
citric acid stimulation, was stored frozen (-80°C) in aliq-
uots for subsequent Db and gp-340 phenotyping and the
ability to mediate adhesion of S. mutans to saliva-coated
hydroxyapatite [10]. Typing of Db+ subjects (hetero- or
homozygous) versus Db- subjects (completely lacking Db
but harbouring two or more of the allelic PRP-1, PRP-2,
PIF or Pa variants), used native alkaline electrophoresis as
described [10]. Missing saliva data for some measure-
ments resulted in final analyses using either 36, 37 or 38
subjects.
Gp-340 phenotyping
Gp-340 I to III typing of parotid saliva was done by West-
ern blot using mAb143 directed to the gp-340 protein
core [9,25]. Saliva samples were boiled in sample buffer
(62.5 mM Tris, 10.1 % glycerol, 2 % SDS, 0.01 % pyronin)
for 5 minutes. Proteins were separated by SDS-PAGE
using precasted 5 % polyacrylamide gels (Bio-Rad, Her-
cules, CA) and running buffer (25 mM Tris, 192 mM gly-
cin, 0.1 % SDS), pH 8.3. Separated proteins were
transferred to an Immobilon-P transfer membrane (0.45
µm, Millipore, Billerica, MA) using 65 mA/membrane for
60 minutes. Subsequently, the membranes were incu-
bated with 5% non-fat dried milk in TBS-T (50 mM Tris,
150 mM NaCl2 and 0.05 % Tween 20), pH 7.4, overnight
at 4°C. The blocked membranes were overlaid with
mAb143, diluted 1:100,000 in TBS-T with 5 % non-fat
dried milk, for one hour at room temperature. After
repeated washes with TBS-T, the membranes were incu-
bated for one hour with horseradish peroxidase-conju-
gated goat anti-mouse IgG (Nordic Biosite, Stockholm,
Sweden) in TBS-T containing 5 % non-fat dried milk. After
repeated washes, bands were detected using chemilumi-
nescence (SuperSignal Substrate, Pierce, Rockford, IL).
Gp-340 I to III phenotyping of saliva from the 38 children
was performed using three gp-340 I to III saliva pheno-
types as typing references. The majority of gp-340 I to III
phenotypes, including all I and III phenotypes, were dis-
tinguished in a single electrophoretic analysis. Some gp-
340 II phenotypes required one or two additional electro-
phoretic runs to safely be distinguished from III. All sali-
vas, except one with a double band character, adhered to
the single band and size typing criteria.
Purification of gp-340 I to III proteins
The gp-340 I to III protein variants were purified from
parotid saliva from three donors as described [9,25].
Briefly, fresh parotid saliva diluted 1:1 in 10 mM phos-
phate buffered saline (PBS, K2HPO4, 150 mM NaCl), pH
6.8, was mixed with a suspension S. mutans Ingbritt (5 ×
109 cells/ml) and allowed to aggregate for 60 minutes at
37°C. After addition of 50 mM EDTA to the pelleted
aggregates, released gp-340 was purified by gel filtration
(Superdex 200 26/60; Pharmacia, Uppsala, Sweden). Pro-
tein concentration and purity of isolated gp-340 I to III
proteins were determined by the DC protein assay (Bio-
Rad) with bovine serum albumin (BSA) as a standard,
densitometric analyses of Coomassie Blue-stained gels
and by Western blotting with mAb143.
Bacterial strains and culturing
S. mutans strains Ingbritt, NG8 and mutant 834 were
grown in Brain Heart Infusion broth (BHI; Difco labora-
tories, Detroit, MI) or Jordan broth [20] at 37°C for 14–
16 hours. The isogenic S. mutans 834 ∆ pac mutant was
generated from wild type strain NG8 by allelic replace-
ment [40] and cultured as described above except for
addition of erythromycin (5 µg/ml) to the media [20].
The  pac  and  spaP  genes were cloned into the vector
pTREX1-usp45LS and expressed on the surface of wild
type  Lactococcus lactis MG1363 as described previously
[21]. Lactococci strains were grown in M17 broth (Merck,
Darmstadt, Germany) at 30°C for 14–16 hours with or
without (wild type MG1363) addition of erythromycin (5
µg/ml) to the media. The bacterial cells were [35S]-labelled
by adding [35S]methionine to the growth medium prior to
culturing as described [20].
Adhesion of bacteria to gp-340 I to III proteins
Bacterial adhesion to hydroxyapatite beads coated with
purified gp-340 protein was analysed [20]. Briefly, after
hydration of the hydroxyapatite beads (5 mg/well, Macro-
Prep ceramic hydroxyapatite Type II, 80 µm, Bio-Rad) in
buffered KCl (1 mM KH2PO4-K2HPO4 buffer, pH 6.5, con-
taining 50 mM KCl, 1 mM CaCl2 and 0.1 mM MgCl2)
overnight at 4°C, the beads were coated with gp-340 pro-
tein (1–6 or 2 µg/ml in buffered KCl) for 60 minutes at
room temperature. The beads were blocked with 5 % BSA
for 60 minutes, washed, and incubated with [35S]methio-
nine-labelled bacteria (5 × 108 cells/ml in buffered KCl
supplemented with 0.5 % BSA) for 60 minutes at room
temperature. After washings, the numbers of bound bac-
teria were measured by scintillation counting.BMC Infectious Diseases 2007, 7:57 http://www.biomedcentral.com/1471-2334/7/57
Page 4 of 8
(page number not for citation purposes)
PLS modelling
The partial least squares (PLS) projection method was per-
formed using the Simca-P software (version 10.5, Umet-
rics AB, Umeå, Sweden) as described [35,36]. PLS
establishes the information in x variables that relates to
the variation in Y in a multivariate model. An X matrix,
containing life-style (e.g. sugar intake, oral hygiene, use of
fluorides) and saliva (e.g. allelic PRP variants, pH, buffer
capacity, gp-340 I to III) variables were modelled against
two different Y matrices. One Y matrix was composed of
eight individual caries measures (i. e. fillings, and dentine
or enamel caries at various tooth surfaces as described)
[10], and another Y matrix consisted of saliva adhesion of
S. mutans (i. e. adhesion of S. mutans to hydroxyapatite
beads coated with parotid saliva diluted 1:1). The X and Y
matrices are described in detail elsewhere [10], except for
the present inclusion of gp-340 I to III as qualitative vari-
ables in the X matrices. The associations between each x-
variable and the Y matrix are expressed as PLS regression
coefficients and VIP-values (Variable Importance in Pro-
jection), where a VIP>1 indicates that the x-variable is
influential for explaining Y.
Statistics
Differences between group means (bacterial adhesion)
were tested with Student's unpaired t test (2 groups) or
ANOVA followed by Tukey's test (>2 groups). Differences
in distribution were tested with the Chi2-test. Group dif-
ferences in caries scores (DMFS or caries increment) and
gp-340 antibody staining/amounts were tested with the
Mann Whitney U test. All tests were 2-sided except for car-
ies increment, and the significance level was set at p <
0.05.
Results
The gp-340 I phenotype correlated with susceptibility to 
caries
The children with high (n = 19) or low caries experience
(n = 19) were phenotyped for gp-340 I to III protein vari-
ants, based on their saliva gp-340 protein banding pattern
by anti-gp-340 mAb143 in Western blot (Figure 1). All
subjects except one displayed the gp-340 I, II or III pheno-
types (10, 23 and 4, respectively). A single subject with a
gp-340 double band character [25] was not considered in
the subsequent analyses.
In multivariate PLS modelling (including the multiple life
style and saliva variables), the gp-340 I to III phenotypes
were correlated with caries experience (Figure 2A). The
variable set rendered a two component PLS modelex-
plaining (R2) and predicting (Q2) the variance in caries
experience at an acceptable level (R2 = 0.56, Q2 = 0.20). In
this model, the gp-340 I phenotype correlated (VIP =
1.37) with a high caries experience, while the gp-340 II
and III phenotypes tended to behave in the opposite way
(VIPs<1) (Figure 2A). The correlation between gp-340 I
phenotype and caries occurred at a level similar to tradi-
tional factors (e.g. sugar intake and oral hygiene) and to
novel host factors (e.g. saliva adhesion of S. mutans and
the susceptibility protein Db) (Figure 2A). The PLS model
was stable, i.e. the correlations for the gp-340 I to III phe-
notypes remained the same when modelling was done
with 1/3 of the subjects randomly and consecutively
excluded (data not shown).
The gp-340 I saliva phenotype mediated increased 
adhesion of S. mutans and AgI/II polypeptides
PLS was used to correlate the gp-340 I to III phenotypes
with the ability of saliva from the children to mediate
adhesion of S. mutans to saliva-coated hydroxyapatite
(Figure 2B). A one component PLS model with R2 = 0.51
and Q2 = 0.27 was generated. The gp-340 I phenotype
coincided with a high adhesion of S. mutans Ingbritt (VIP
= 1.47), while the opposite tended to be true for gp-340
phenotypes II (VIP<1.0) and III (VIP = 1.06) (Figure 2B).
We next investigated if purified gp-340 proteins I to III
mediated different adhesion levels of S. mutans through
recognition by AgI/II proteins (Figures 3A to 3C). The gp-
340 I protein promoted markedly higher adhesion of S.
mutans Ingbritt and NG8 compared to gp-340 II and III
(Figure 3A, 46%, 25% and 16% adhering cells, respec-
tively, p < 0.001 for I vs II or III). S. mutans mutant 834,
derived from S. mutans NG8 and abrogated in expression
Saliva gp-340 phenotypes I to III Figure 1
Saliva gp-340 phenotypes I to III. Illustration of repre-
sentative gp-340 I to III saliva phenotypes observed among 
children upon Western blotting of parotid saliva samples 
with mAb143. Unreduced parotid saliva samples were sepa-
rated by SDS-PAGE on 5% gels. Molecular masses (kDa, left) 
and gp-340 I to III phenotype (top) of the three saliva donors 
are marked.BMC Infectious Diseases 2007, 7:57 http://www.biomedcentral.com/1471-2334/7/57
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of PAc (AgI/II) protein, showed no adhesion to gp-340 I
(Figure 3B). Moreover, the gp-340 I protein mediated sev-
eral fold higher adhesion than gp-340 II and III of Lacto-
coccus lactis expressing AgI/II polypeptides from strains
Ingbritt and NG8 (SpaP and PAc, respectively) (Figure
3C). Wild-type vector control L. lactis MG1363 cells not
expressing any AgI/II protein did not adhere to gp-340
proteins I, II or III (Figure 3C). Taken together, these
results suggest that gp-340 I is preferentially recognized by
the S. mutans AgI/II polypeptide and promotes high affin-
ity adhesion and oral colonization by pathogenic S.
mutans bacteria.
The gp-340 I phenotype coincides with an increased caries 
increment and the caries susceptibility protein Db
To validate our findings from the PLS model (using eight
dependent Y caries measures), we also analysed the gp-
340 I versus II/III phenotypes for differences in 2-year car-
ies increment by means of traditional statistics (Figure
4A). The caries increment was higher for gp-340 I com-
pared to gp-340 II/III phenotypes (p = 0.027, Figure 4A).
In addition, the gp-340 I versus II/III phenotypes did not
differ significantly in gp-340 amounts as inferred from
mAb143 staining of gp-340 in individual salivas upon
Western blotting (data not shown).
We have previously reported that the allelic acid PRP pro-
tein variant Db correlates with a high caries experience
[10]. The present findings showed the gp-340 I protein to
be more common among Db+ subjects (5/11 = 45 %),
than among Db- subjects (4/26 = 15%, p = 0.051) har-
bouring other allelic acidic PRP variants (i.e. PRP-1, PRP-
2, PIF, Pa) (Figure 4B). The phenotypes positive for both
gp-340 I and Db experienced more caries than those neg-
ative for both proteins (4.8 versus 1.5 DMFS, respectively,
p = 0.023, Figure 4C).
Discussion
This study suggests for the first time a potential role for gp-
340/DMBT1 polymorphisms in human diseases beyond
cancer, as it implies the gp-340 I protein as a caries suscep-
tibility protein. Accordingly, the gp-340 I phenotype cor-
related positively with caries experience when analysed
among other variables by PLS modelling, as well as coin-
cided with an increased 2-year caries increment. Moreo-
ver, the gp-340 I phenotype correlated positively with
saliva adhesion of S. mutans, an intermediate caries meas-
ure, and purified gp-340 I protein mediated increased
adhesion of the same organism and its major AgI/II sur-
face adhesin. Finally, the gp-340 I protein was overrepre-
sented in subjects positive for Db, another caries
susceptibility factor.
It is possible that gp-340 I acts as a caries susceptibility
protein by increasing the adhesion and colonisation of S.
mutans. Gp-340 I positive subjects displayed increased
saliva adhesion of S. mutans, a function previously associ-
Association of gp-340 I with increased S. mutans adhesion Figure 3
Association of gp-340 I with increased S. mutans 
adhesion. (A-C) Bacterial adhesion to purified gp-340 I toIII 
proteins coated on hydroxyapatite surfaces (2 ug/ml for fixed 
amounts of protein). Data are presented as mean ± SE from 
double measurements of repeated experimental runs. (A) 
Adhesion of S. mutans Ingbritt to gp-340 I vs II or III (* p < 
0.001, respectively). Similar results were obtained irrespec-
tive of culturing in BHI or Jordan broth. (B) Adhesion of S. 
mutans NG8 and isogenic mutant 834, disrupted in the pac 
(AgI/II polypeptide) gene, to gp-340 I protein (* p < 0.001). 
(C) Adhesion of L. lactis expressing SpaP (from S. mutans) or 
vector control (wild-type) L. lactis MG1363 to serial dilutions 
of gp-340 I vs II or III (* p < 0.001, respectively). Similar 
results were obtained when L. lactis expressing PAc was 
bound to serial dilutions of gp-340 I to III.
Association of gp-340 I with caries susceptibility and saliva  adhesion of S. mutans Figure 2
Association of gp-340 I with caries susceptibility and 
saliva adhesion of S. mutans. PLS correlation coefficients, 
with 95 % CI, for (A) gp-340 I to III phenotypes and some 
selected caries-associated variables from modelling with car-
ies experience in the children as dependent variable, and (B) 
gp-340 I to III phenotypes from modelling with saliva adhe-
sion of S. mutans in the children as dependent variable.BMC Infectious Diseases 2007, 7:57 http://www.biomedcentral.com/1471-2334/7/57
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ated with caries development in the same cohort. Moreo-
ver, purified gp-340 I protein enhanced adhesion of both
S. mutans and lactococci expressing the AgI/II adhesin
(SpaP or PAc) from S. mutans. The gp-340 protein I may
exhibit adhesion epitopes of higher affinity or availability
than variants II and III. By contrast, neither lactococci
expressing AgI/II nor S. mutans discriminated between
variants I to III when aggregated, as opposed to when
adhered, by the gp-340 size variants [25]. We speculate,
although only gp-340 I to III proteins purified from single
donors have been tested, that aggregation (by fluid gp-
340) and adhesion (by surface adsorbed gp-340) may
involve different recognition epitopes for S. mutans, and
that the surface-associated epitope alone may be affected
by the gp-340 I to III polymorphisms. This interpretation
is consistent with the generally deviating adhesive behav-
iour of fluid and surface adsorbed gp-340 toward different
streptococcal phenotypes, and that both gp-340 and AgI/
II [19,41] are multidomain polypeptides with several
potential binding sites. Finally, since many oral viridans
streptococci express AgI/II polypeptides interacting with
gp-340, the gp-340 protein I may besides S. mutans pro-
mote colonization of cariogenic phenotypes of additional
streptococcal species.
The mucin-like and multifunctional gp-340 I protein var-
iant may differ in a variety of its protein and cellular lig-
and interactions and, consequently, impair protection
against caries by a multiplicity of mechanisms. In this
context, it is noteworthy that gp-340 I versus II/III pro-
teins appears to differ in glycosylation [25], and that
VNTR associated with cancer are present in gp-340 [42].
Both carbohydrate modifications, involving SID domains
with bacterial ligand interactions, and protein modifica-
tions, involving SRCR domains with protein and cellular
ligand interactions, may accordingly modify the biologi-
cal properties of gp-340/DMBT1. Salivary MUC5B and
MUC7 [43,44] also harbour size variants associated with
variations in VNTR and glycosylation. At present, how-
ever, we do not know if the gp-340 I to III size variations
between subjects occur also in tissues other than saliva.
Anyhow, gp-340 is expressed on macrophages and at var-
ious oro-gastro-intestinal tissue sites involved in immu-
nological surveillance. We hypothesize that the down
stream immunological processing of AgI/II complexes
with gp-340 may be impaired in gp-340 I phenotypes. In
the case of S. mutans, AgI/II is a major adhesin and vaccine
candidate and further studies on innate and immune
modifying properties of gp-340 polymorphisms may be
fruitful.
A role for gp-340 I in susceptibility to caries is consistent
with its potential link to Db, a caries susceptibility PRP
protein variant or allele. Gp-340 I was over represented in
Db+ as compared to Db- subjects, and gp-340 I+/Db+
phenotypes experienced more caries than those negative
for both proteins. The gp-340 and PRP scavenger protein
families are located on separate chromosomes, 10 and 12,
respectively, but may cooperate in adhesion or molecular
networking to neutralize non self ligands in saliva. Nota-
bly, both gp-340 I and Db correlate positively with saliva
adhesion of S. mutans [10] and gp-340 interacts with mul-
tiple salivary proteins, e.g. S-IgA, lactoferrin, SpD and
MUC5B, and co-operate with SpD to neutralize influenza
virus in saliva [30].
The present work further emphasizes the usefulness of the
PLS method to identify potential target molecules for host
susceptibility or resistance in small clinical samples. Nota-
bly, the potential PRP-1 resistance polypeptide targeted by
this approach releases via bacterial proteolysis an RGRPQ
peptide affecting key properties of biofilm formation (i. e.
adhesion, proliferation and local pH) in vitro and in vivo
[37,38]. Whether the gp-340 size variants are subject to
similar proteolytic events or will provide similar drug can-
didates remains to be determined. Moreover, the poten-
tial gp-340 I and Db susceptibility markers are present at
about a 15–20% prevalence level. However, it is reasona-
ble to assume that the predictive value of single suscepti-
bility factors – similar to many other potentially
polygenetic diseases – will be low for the multifactorial
and chronic caries disease [45]. Finally, further studies on
Association of the gp-340 I phenotype with increased caries  increment and the caries susceptibility allele Db Figure 4
Association of the gp-340 I phenotype with increased 
caries increment and the caries susceptibility allele 
Db. (A) Plot of the individual 2-year caries increment scores 
for the gp-340 phenotypes I to III (gp340 I versus II/III, 
median scores 4 and 0, respectively, p = 0.027). (B) Numbers 
of gp-340 I positive subjects (■ ) among Db+ and Db- sub-
jects (* p = 0.051). (C) Caries experience (mean DMFS ± SE) 
in subjects positive for gp-340 I and Db (gp-340I/Db+) versus 
subjects negative for both proteins (gp-340II, III/Db-) (* p = 
0.023).BMC Infectious Diseases 2007, 7:57 http://www.biomedcentral.com/1471-2334/7/57
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host polymorphisms and their evaluation in disease pro-
filing and risk assessment using larger clinical samples
may reveal the usefulness of the gp-340 and other host
polymorphisms in risk assessment of caries in a clinical
setting.
Conclusion
This report shows that the scavenger protein gp-340 size
variant I coincides with host susceptibility to dental caries,
and that increased AgI/II-mediated adhesion of the cario-
genic bacterium S. mutans may be an underlying mecha-
nism.
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